Clinical Trials Logo

Clinical Trial Summary

This study plans to enroll 69 subjects of endometrial cancer and 5-10 subjects of sarcoma of uterus. The experimental set is divided into lead-in trial and formal trial. The lead-in trial includes 9 subjects to observe the safety of the combination and determine the dosage of anlotinib dihydrochloride capsules before the formal phase. The formal trial includes 60 subjects of endometrial cancer and 5-10 subjects of sarcoma of uterus. The purpose is to evaluate efficacy and safety of TQB2450 injection combined with chemotherapy ± anlotinib hydrochloride capsules for first-line treatment and maintenance treatment of patient with advanced endometrial cancer or sarcoma of uterus, and explore biomarkers related to efficacy, mechanism of action, safety and/or pathological mechanisms, the surgical conversion rate. ORR is the primary endpoint.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05481645
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Xiaojun Chen, Doctor
Phone 021-33189900
Email cxjlhjj@163.com
Status Recruiting
Phase Phase 2
Start date August 22, 2022
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04574284 - A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer Phase 2
Withdrawn NCT06046274 - GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Phase 2
Recruiting NCT05112991 - Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer Phase 2
Not yet recruiting NCT05106127 - Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem Phase 2
Completed NCT01289041 - BKM120 as Second-line Therapy for Advanced Endometrial Cancer Phase 2
Not yet recruiting NCT05077215 - Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer Phase 3